Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Opening Session Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Apr

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Opening Session Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Metastatic NSCLC Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy

High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity

Methylation-Based AI Model Classifies Tumors of Unknown Origin

Initial Data Shows Safety for WEE1 PKMYT1 Inhibitor Combination in Advanced Solid Tumors

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?